Overcoming Receptor Tyrosine Kinase mediated resistance to BRAF Inhibitors in metastatic melanoma, colorectal and lung cancers.

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1042980

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

The drug Vemurafenib results in good responses in melanoma patients. However, patients become resistant to treatment. We have identified specific receptors that can cause Vemurafenib resistance, which can be overcome by combination treatment with drugs to these receptors. We will assess melanoma patient samples for expression of these receptors which will be highly beneficial for selecting combination treatments to prevent drug resistance and ensure better prolonged outcomes.

Funded Activity Details

Start Date: 01-01-2013

End Date: 01-01-2017

Funding Scheme: Project Grants

Funding Amount: $574,958.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Cancer Therapy (excl. Chemotherapy and Radiation Therapy)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

cancer therapy | combination therapy | drug resistance | kinase inhibitors | melanoma | receptor tyrosine kinase (RTK) | targeted therapy

Related Links